14th August 2018
- 0 comments
Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, has announced that its Group Business Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, has completed an oversubscribed £65 million Series B financing following strong interest from investors.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.